Glaucoma is an irreversible progressive optic neuropathy, for which the major proven
treatment is to lower the intraocular pressure (IOP). Five groups of IOP‐lowering eye drops …

Aqueous humor flows out of the eye primarily through the conventional outflow pathway that
includes the trabecular meshwork and Schlemm's canal. However, a fraction of aqueous …

PURPOSE:: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-
adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure …

Blindness affects 60 million people worldwide. The leading causes of irreversible blindness
include age-related macular degeneration, retinal vascular diseases and glaucoma. The …

The uveoscleral outflow route was described more than 40years ago. Part of aqueous
leaves the eye through the iris root. The ciliary muscle, and there are large species …

A number of pharmacological targets are exploited to modify the parameters in the
Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the …

Objective AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine
transporter. The objective of this 28-day study was to evaluate the ocular hypotensive …

For some time the medical treatment of glaucoma has consisted of topical β-blockers,
adrenergic agents, miotics and oral carbonic anhydrase inhibitors (CAIs). However, the …

Purpose: To determine the mechanism by which topically applied AR-13324, a rho kinase
inhibitor, and an inhibitor of the norepinephrine transporter, reduces intraocular pressure …

Objective: Brimonidine tartrate is a highly selective α 2-agonist. This study investigates the
safety and efficacy of 0.2% brimonidine administered twice daily for 1 year in patients with …